# Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics

> **NCT06689527** · PHASE1 · COMPLETED · sponsor: **Santhera Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Drug Interaction

## Interventions

- **DRUG:** Vamorolone
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT06689527
- **Lead sponsor:** Santhera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-13
- **Primary completion:** 2024-09-24
- **Final completion:** 2024-10-16
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06689527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06689527, "Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06689527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*